H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $80 from $75 and keeps a Buy rating on the shares. The firm says aleniglipron exhibits “structural uniqueness, with slightly distinct properties that could drive differentiated weight-loss outcomes in the ACCESS trials.” It views the orforglipron and danuglipron data as encouraging for aleniglipron.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating
- Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning
- Promising Developments in Weight Management Propel Buy Rating for Structure Therapeutics
- Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs
- Apple downgraded, Reddit upgraded: Wall Street’s top analyst calls
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue